Search Results - "Lloansi Vila, A."

First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study by García Alfonso, P, Valladares-Ayerbes, M, Muñoz Luengo, J, Pimentel, P, Viéitez, J M, Cruz Hernandez, J J, Llanos, M, Garcia Girón, C, Salud Salvia, A, Lloansí Vila, A

Get full text

1410P Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study) by Reguart Aransay, N., Sánchez, J., Juan Vidal, O.J., Aguilo Domingo, M., Arriola, E., López, C., Botella, X., Cots, F., Montironi, C., Palanca, S., Borràs, E., Masfarre Pinto, L., Planellas, L., Lloansi Vila, A.

Get full text

382P Sequential RAS mutation status evaluation in circulating free DNA (cfDNA) in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) starting first-line (1L) treatment with panitumumab (P) and chemotherapy (CT). PERSEIDA (Idylla Cohort) study by Valladares, M., Safont Aguileria, M.J., González-Flores, E., García Alfonso, P., López Muñoz, A.M., Aranda Aguilar, E., Falco Ferrer, E., Rodriguez-Salas, N., Cirera, L., Llanos-Munoz, M., Aparicio, J., Pimentel, P., Castillo Trujillo, A.O., Salgado Fernandez, M., Salud Salvia, M.A., Vidal Tocino, R., Massuti Sureda, B., Garcia-Carbonero, R., Vicente Conesa, M.A.D.L.A., Lloansi Vila, A.

Get full text

455P Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478) by Valladares-Ayerbes, M., Safont, M.J., González-Flores, E., García-Alfonso, P., Aranda Aguilar, E., López Muñoz, A.M., Cirera Nogueras, L., Falco Ferrer, E., Rodriguez Salas, N., Aparicio, J., Llanos, M., Castillo Trujillo, O.A., Pimentel Cáceres, P., Cruz-Hernández, J.J., Salgado Fernández, M., Salud Salvia, A., Garcia-Carbonero, R., Massuti Sureda, B., Vicente Conesa, M.A., Lloansi Vila, A.

Get full text

Sequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first-line (1L): PERSEIDA study by Valladares-Ayerbes, M., García-Alfonso, P., Luengo, J Muñoz, Cáceres, P Pimentel, Viéitez, J.M., Cruz-Hernández, J.J., Llanos, M., Girón, C Garcia, Cirera, L., Vila, A Lloansí

Get full text

531PD - Sequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first-line (1L): PERSEIDA study by Valladares-Ayerbes, M., García-Alfonso, P., Luengo, J Muñoz, Cáceres, P Pimentel, Viéitez, J.M., Cruz-Hernández, J.J., Llanos, M., Girón, C Garcia, Cirera, L., Vila, A Lloansí

“…Genotyping on cfDNA offers potential advantages in clinical practice for pt selection and serial monitoring of treatment (Tx) efficacy. Clinical relevance of…”
Get full text

531PDSequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first-line (1L): PERSEIDA study by Valladares-Ayerbes, M, García-Alfonso, P, Luengo, J Muñoz, Cáceres, P Pimentel, Viéitez, J M, Cruz-Hernández, J J, Llanos, M, Girón, C Garcia, Cirera, L, Vila, A Lloansí

“…Abstract Background Genotyping on cfDNA offers potential advantages in clinical practice for pt selection and serial monitoring of treatment (Tx) efficacy…”
Get full text

546PFirst-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study by García Alfonso, P, Valladares-Ayerbes, M, Muñoz Luengo, J, Pimentel, P, Viéitez, J M, Cruz Hernandez, J J, Llanos, M, Garcia Girón, C, Salud Salvia, A, Lloansí Vila, A

Get full text